/ASND
ASND Stock - Ascendis Pharma A/S
Healthcare|BiotechnologyNASDAQ
$215.05+3.01%
+$6.29 (+3.01%) • Jan 13
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.78
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+34.4%upside
Target: $289.03
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ASND
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$212.90 – $217.20
TARGET (TP)$289.00
STOP LOSS$197.85
RISK/REWARD1:4.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.45
52W High$229.94
52W Low$118.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $363.64M | $266.72M | $51.17M | $7.78M | $6.95M |
| Gross Profit | $319.38M | $222.32M | $39.04M | $4.25M | $6.95M |
| Gross Margin | 87.8% | 83.4% | 76.3% | 54.7% | 100.0% |
| Operating Income | $-278,763,000 | $-455,541,000 | $-561,814,000 | $-451,792,000 | $-330,620,000 |
| Net Income | $-378,084,000 | $-481,447,000 | $-583,194,000 | $-383,577,000 | $-418,955,000 |
| Net Margin | -104.0% | -180.5% | -1139.6% | -4931.6% | -6025.5% |
| EPS | $-6.53 | $-8.55 | $-10.40 | $-7.00 | $-8.28 |
Company Overview
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ASNDBeat Rate
50%
Last 18 quarters
Avg Surprise
-6.6%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-1.17
Q4 2025
EPS Surprise History
Q1 24
+24.1%
$-1.66vs$-2.19
Q2 24
-53.3%
$-2.48vs$-1.62
Q3 24
-33.1%
$-2.05vs$-1.54
Q4 24
+1.1%
$-1.81vs$-1.83
Q1 25
+43.3%
$-0.68vs$-1.20
Q2 25
-6.4%
$-1.66vs$-1.56
Q3 25
+34.5%
$-0.93vs$-1.42
Q4 25
-185.4%
$-1.17vs$-0.41
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $0.13 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.41 | $-1.17 | -185.4% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-1.42 | $-0.93 | +34.5% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-1.56 | $-1.66 | -6.4% | ✗ MISS |
Q1 2025 | Feb 12, 2025 | $-1.20 | $-0.68 | +43.3% | ✓ BEAT |
Q4 2024 | Nov 14, 2024 | $-1.83 | $-1.81 | +1.1% | ✓ BEAT |
Q3 2024 | Sep 3, 2024 | $-1.54 | $-2.05 | -33.1% | ✗ MISS |
Q2 2024 | May 2, 2024 | $-1.62 | $-2.48 | -53.3% | ✗ MISS |
Q1 2024 | Feb 7, 2024 | $-2.19 | $-1.66 | +24.1% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-2.55 | $-3.08 | -21.0% | ✗ MISS |
Q3 2023 | Aug 16, 2023 | $-3.09 | $-1.54 | +50.2% | ✓ BEAT |
Q2 2023 | Apr 27, 2023 | $-2.93 | $-2.18 | +25.6% | ✓ BEAT |
Q1 2023 | Feb 16, 2023 | $-2.74 | $-3.96 | -44.5% | ✗ MISS |
Q4 2022 | Nov 2, 2022 | $-2.52 | $-3.05 | -21.0% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-2.19 | $-1.50 | +31.5% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-2.09 | $-2.31 | -10.5% | ✗ MISS |
Q1 2022 | Mar 2, 2022 | $-2.57 | $-2.06 | +20.1% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-2.63 | $-1.69 | +35.8% | ✓ BEAT |
Q3 2021 | Aug 25, 2021 | $-2.75 | $-3.01 | -9.5% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about ASND
What is ASND's current stock price?
Ascendis Pharma A/S (ASND) is currently trading at $215.05 per share. The stock has moved +3.01% today.
What is the analyst price target for ASND?
The average analyst price target for ASND is $289.00, based on 1 analyst.
What sector is Ascendis Pharma A/S in?
Ascendis Pharma A/S operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ASND's market cap?
Ascendis Pharma A/S has a market capitalization of $12.96 billion, making it a large-cap company.
Does ASND pay dividends?
No, Ascendis Pharma A/S does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBBIO
BridgeBio Pharma, Inc.
$79.11
Mkt Cap: $15.1B
BMRN
BioMarin Pharmaceutical Inc.
$55.20
Mkt Cap: $10.6B
EXEL
Exelixis, Inc.
$44.08
Mkt Cap: $11.8B
GH
Guardant Health, Inc.
$106.89
Mkt Cap: $13.3B
IONS
Ionis Pharmaceuticals, Inc.
$79.48
Mkt Cap: $12.6B
MDGL
Madrigal Pharmaceuticals, Inc.
$493.90
Mkt Cap: $11.0B
MRNA
Moderna, Inc.
$39.60
Mkt Cap: $15.5B
ROIV
Roivant Sciences Ltd.
$23.44
Mkt Cap: $16.3B
RVMD
Revolution Medicines, Inc.
$119.95
Mkt Cap: $23.2B
SMMT
Summit Therapeutics Inc.
$16.81
Mkt Cap: $12.5B
Explore stocks similar to ASND for comparison